Psychology by BogdanovaThe Encyclopedia of Psychology for the Artificial Era

RESEARCH DOSSIER

Multiple Sclerosis: Fatigue, Self-Management, and Participation

Abstract. Multiple sclerosis (MS) fatigue is a fluctuating, multidimensional experience with measurable consequences for daily activity, employment, relationships, and participation. This fundamental research monograph examines the historical development of MS fatigue science, distinctions between perceived fatigue and performance fatigability, neurobiological and psychological explanations, measurement validity, and the effects of interventions on symptoms and functioning. Evidence is critically integrated from fatigue-scale validation studies, ecological momentary assessment, longitudinal employment research, randomized trials of energy conservation, cognitive behavioral therapy, exercise and pharmacological interventions, and systematic and umbrella reviews, including research published in 2026. Detailed comparisons of TREFAMS-ACE, TRIUMPHANT-MS, COMBO-MS, FACETS+, blended therapy, and digital self-management distinguish active-comparator effects, placebo-controlled estimates, treatment durability, and limits of subgroup inference. The synthesis finds that improvements in fatigue, self-management capacities, and valued social participation can diverge. It identifies unresolved questions of causal mechanisms, longitudinal maintenance, measurement equivalence, equity, and translation into real-world environments. An integrated participation-centered account provides the organizing framework for future research without claiming that these descriptive levels constitute a newly validated causal model.

Keywords: multiple sclerosis; fatigue; fatigability; fatigue impact; self-management; cognitive behavioral therapy; energy conservation; exercise rehabilitation; occupational participation; rehabilitation psychology; activities of daily living; ecological momentary assessment; COMBO-MS; TREFAMS-ACE; TRIUMPHANT-MS

The Scientific Object: Fatigue, Self-Management, and Participation in Multiple Sclerosis

Multiple sclerosis (MS) is an immune-mediated disorder of the central nervous system in which inflammatory injury, demyelination, and neuroaxonal pathology can alter neurological functioning over time. The subject of this research dossier is the psychological and rehabilitation relationship among fatigue, the organization of self-management, and participation in personally valued activities. The primary outcome of interest is not a single laboratory score. It is the capacity to sustain valued roles, choices, relationships, and everyday activity under variable symptoms and environmental constraints. The diagnostic background is defined by specialist neurological criteria, whose 2024 revision was published in 2025; the revised criteria concern diagnosis and cannot themselves explain any individual patient's fatigue Montalban et al. (2025).

Fatigue is a subjective, multidimensional phenomenon with physical, cognitive, motivational, and social consequences. Self-management comprises learned practices for monitoring symptoms, adjusting activity, working with healthcare teams, pursuing goals, and negotiating environmental support. Participation describes involvement in life situations, including employment, education, family, citizenship, intimacy, and community life. These constructs overlap in lived experience but require separate observation. Fatigue intensity, fatigue impact, performance fatigability, self-management confidence, and participation are distinct measurement targets. The World Health Organization's International Classification of Functioning, Disability and Health (ICF) supplies an influential framework for relating health conditions, bodily functions, activities, participation, and environmental factors WHO (2001).

This study uses a critical, narrative integration of primary randomized trials, longitudinal studies, ecological momentary assessment, scale-validation studies, systematic reviews, and clinical guidance. Searches and source checks emphasize PubMed-indexed originals, the Cochrane Library, the WHO, NICE, and peer-reviewed literature through November 2026. This work has no preregistered search protocol, dual screening, complete database export, or independent meta-analysis. Conclusions are therefore graded through transparent comparison of study designs and outcomes rather than through invented claims of comprehensive systematic-review coverage. The object is MS-specific rehabilitation and psychological participation; general chronic-illness self-management and fatigue across other conditions belong to related research objects NICE (2022/2026) Hawas et al. (2026).

The foundational question is how biological limitations, perceptions of effort, expectation, sleep, mood, behavior, clinical services, and material environments combine to affect the actual pursuit of life projects. A treatment may reduce a fatigue questionnaire score without restoring employment. Another may improve planning and decision-making without changing measured fatigue. A third may change capacity through physical conditioning but leave participation obstructed by inaccessible transportation or workplace arrangements. This separation is crucial to evaluating therapeutic evidence, avoiding the misattribution of disability to individual motivation, and connecting psychological rehabilitation to the social conditions of participation WHO (2001) van den Akker et al. (2017).

Historical Foundations of the Research Program

Fatigue entered MS clinical literature well before modern disease-modifying treatment, but systematic psychological investigation accelerated when researchers began measuring patients' reported experience independently of conventional neurological disability scales. Krupp and colleagues' 1988 interview comparison of 32 people with MS and 33 healthy adults found more frequent and severe fatigue in the MS group; the investigators reported that fatigue was not reducible to the depression or global impairment variables examined in that sample. The study was small, observational, and historically important for establishing a separate symptom domain, not for proving a unitary neurological mechanism Krupp et al. (1988).

In 1989, Krupp and colleagues introduced the Fatigue Severity Scale (FSS) in a study involving people with MS, systemic lupus erythematosus, and healthy adults. Its development made fatigue accessible to reproducible patient reporting, although the original sample sizes were modest and its content emphasizes impact and perceived severity rather than directly measuring physiological fatigability. Later work evaluated multiple-domain scales, including the Modified Fatigue Impact Scale (MFIS), and demonstrated that fatigue could be treated as a measurable, yet multidimensional, feature of rehabilitation rather than an incidental symptom Krupp et al. (1989) Kos et al. (2005).

A second phase introduced rehabilitation approaches centered on energy management and occupational functioning. Mathiowetz and colleagues' randomized study of 169 participants, published in 2005, examined a six-week energy-conservation course and identified benefits in physical and social fatigue impact, selected quality-of-life domains, and perceived self-efficacy for implementing strategies. Its delayed-treatment crossover design helped establish a practical intervention tradition, while outcomes still depended substantially on self-report. A subsequent one-year follow-up extended attention from immediate training to maintenance of behavioral change Mathiowetz et al. (2005) Mathiowetz et al. (2007).

A third phase developed structured cognitive-behavioral interventions and comparative randomized research. The FACETS trial investigated a group program integrating cognitive-behavioral and energy-effectiveness techniques. TREFAMS-ACE examined individualized cognitive behavioral therapy (CBT) against MS-nurse consultations, incorporating participation alongside fatigue as an explicit outcome. More recent trials compared behavioral care with pharmacological treatments and tested online approaches. This progression reflects a methodological shift from establishing whether fatigue exists to determining which components of symptom burden and functioning can be changed, for whom, by which mechanism, and over what time horizon Thomas et al. (2013) van den Akker et al. (2017) Braley et al. (2024).

Defining Fatigue, Fatigability, and Functional Burden

The word fatigue is used for at least three partly separable targets: a current experience of tiredness or depleted energy, a retrospective judgment about the interference of that experience with everyday life, and a change in performance during sustained cognitive or physical tasks. Kluger, Krupp, and Enoka proposed a conceptual taxonomy distinguishing perceived fatigue and fatigability. Enoka and colleagues later developed the argument that momentary fatigue experiences and objective task-related performance decline should be evaluated separately, especially because self-reported retrospective scales blend symptoms with beliefs about capacity and past activity Kluger et al. (2013) Enoka et al. (2021).

Physical fatigue may be expressed as perceived effort during walking, resistance exercise, standing, or household tasks. Cognitive fatigue may be expressed as difficulty sustaining concentration, processing information, or managing prolonged interpersonal demands. Both can occur during the same day, and neither maps automatically onto objective weakness or neuropsychological deficit. Mood symptoms, anxiety, poor sleep, pain, heat sensitivity, and medication-related effects can aggravate fatigue and complicate attribution. NICE explicitly recommends assessment for sleep problems, pain, spasticity, bladder dysfunction, medication effects, infections, anemia, thyroid disease, anxiety, and depression instead of assuming that every episode has the same MS-related cause NICE (2022/2026).

For research purposes, perceived fatigue severity is a subjective rating of experience, fatigue impact is a report of life interference, and objective fatigability is a measurable decline in performance under defined task demands. Their correlations may be modest because tasks, environmental support, behavior, and compensatory choices affect the correspondence. Self-report is indispensable for a subjective phenomenon, while performance-based tests provide complementary information. A program may alter appraisal, confidence, or activity selection and reduce reported impact with little change in objective fatigability; those changes can still matter, but the causal interpretation must be stated precisely Kluger et al. (2013) Enoka et al. (2021).

MS fatigue is also temporally organized. A weekly questionnaire can reflect anticipated difficulty, the most disruptive event, or an average of several different days. Repeated assessments reveal peaks, recovery periods, and context-sensitive variations that a single score hides. A complete clinical description therefore asks when fatigue arises, which activities provoke it, what recovery opportunities exist, and whether it changes participation. These questions transform a generic symptom complaint into a functional and testable account of a person's day Powell et al. (2017) Kratz et al. (2017).

Neurobiological and Psychological Explanatory Levels

The presence of inflammatory and neurodegenerative disease supplies an essential biological context for MS fatigue. Proposed contributing pathways include central network inefficiency, altered motor and cognitive effort, disrupted arousal regulation, neuroimmune processes, sleep disturbance, and deconditioning. These are explanatory candidates acting at different levels. A statistical correlation between imaging abnormalities or inflammatory markers and a fatigue rating cannot establish that any single pathway produces the entire syndrome. Symptom heterogeneity and variable disease courses make one-mechanism explanations especially fragile Enoka et al. (2021) Kluger et al. (2013).

Psychological models examine symptom interpretation, beliefs about effort, activity-rest cycles, coping, attentional allocation, stress, and behavioral avoidance. A person who expects severe delayed exhaustion may modify activity before a demanding task; such modification can be adaptive under genuine physiological constraints, while prolonged restriction can also reduce conditioning and occupational opportunity. The same observable behavior therefore has different meaning according to objective load, recent symptoms, risk, goals, and environmental demands. CBT interventions often address patterns of thought, sleep, activity, and problem solving, but the clinical evidence does not imply that fatigue is caused by beliefs alone van den Akker et al. (2017) Braley et al. (2024).

An ecological account treats fatigue as the result of interacting organism, task, and setting. A person's workday requires specific cognitive and physical resources; commuting, sensory load, unreliable rest periods, social expectations, and inaccessible accommodations can magnify the burden. The ICF differentiates what a person can do in a standardized setting from what the person actually does in a particular environment. This allows psychological care, occupational rehabilitation, physical training, workplace adjustment, and social support to be studied as potentially complementary interventions rather than competing explanations WHO (2001) van Egmond et al. (2024).

A clinically useful model must account for feedback. Symptom worsening can disrupt sleep, activity, and mood; fewer opportunities for meaningful engagement can change motivation and self-efficacy; reduced participation may increase isolation, financial strain, and treatment burden. Reciprocal pathways are plausible, but temporal sequence must be tested with repeated measures, natural experiments, or interventions. Cross-sectional associations alone do not determine which feedback process is the cause and which is the consequence Kratz et al. (2017) Powell et al. (2017).

Measurement, Psychometrics, and Interpretation

The FSS is widely recognized as an early measure of fatigue severity and its interference with activities. The MFIS measures perceived effects of fatigue across physical, cognitive, and psychosocial domains, while other studies use the Checklist Individual Strength, fatigue-specific motor and cognitive scales, or simple intensity ratings. No single instrument captures the full causal structure of fatigue. Scale choice should follow the primary research question: state-level intensity, perceived consequences, response to therapy, task endurance, or occupational participation Krupp et al. (1989) Kos et al. (2005).

Validation requires more than a reported internal-consistency coefficient. Researchers must examine content validity, factor structure, translation, test-retest reliability, responsiveness, interpretability, floor and ceiling effects, and differential item functioning across levels of disability and language groups. Kos and colleagues assessed the MFIS across four European countries; subsequent Rasch-oriented work has examined the dimensional assumptions of the Fatigue Impact Scale family. Comparability between populations is an empirical question rather than a property guaranteed by sharing an instrument name Kos et al. (2005) Piscitelli et al. (2024).

The Multiple Sclerosis Impact Scale (MSIS-29) provides patient-based measurement of physical and psychological consequences of MS. Hobart and colleagues introduced it in 2001; its content is broader than fatigue and illustrates why disease impact and fatigue are different constructs. An occupational or social participation outcome needs still another instrument or direct indicator. A study using only MFIS change can make credible claims about MFIS change, while claims about restored social roles require actual participation data Hobart et al. (2001) van den Akker et al. (2017).

Outcome interpretation must distinguish within-group improvement from a treatment effect. People may improve through regression to the mean, increased attention, seasonal changes, changed medication, expectation, or study participation. A comparison among several active arms without a usual-care control does not establish that each intervention outperforms doing nothing. The COMBO-MS study, for example, gives strong evidence about the comparative performance of its three randomized active treatments, while its absence of a placebo arm limits conclusions about absolute efficacy. By contrast, placebo-controlled drug comparisons address a different inference Braley et al. (2024) Nourbakhsh et al. (2021).

Daily Variability, Sleep, Mood, and Context

Ecological momentary assessment (EMA) repeatedly asks participants about symptoms as they occur. In a 2017 study, Powell and colleagues studied 38 people with relapsing-remitting MS and 38 controls over four weekdays using six daily assessments; fatigue fluctuated across time, and associations with stressors, mood, exertion, and sleep differed partly between groups. The result shows why a retrospective monthly summary can fail to represent the context in which symptoms actually constrain decisions Powell et al. (2017).

In another 2017 observational study, Kratz, Murphy, and Braley monitored 107 ambulatory adults with MS five times daily for seven consecutive days. Fatigue and pain displayed considerable within-person variability, with fatigue showing a pronounced rise across the day. This is a community-based repeated-measures finding and does not establish an individualized causal rule that all people with MS become most fatigued at the same hour Kratz et al. (2017).

Sleep disorders require particular attention because tiredness, sleepiness, and fatigue are often conflated. Sleep disruption from nocturia, pain, spasticity, altered circadian schedules, breathing-related sleep disorders, and medication effects may contribute to symptom burden. Depression and anxiety can coexist with fatigue without accounting for every case. A differential assessment is therefore a prerequisite to interpreting an intervention response: changing an undetected sleep disorder may change fatigue without directly affecting the pathological activity of MS NICE (2022/2026).

EMA also changes the theory of self-management. A person may have few symptoms at the beginning of the day but little recoverable capacity later; activity schedules and work accommodations have temporal properties. Researchers can combine symptom diaries, mobility measures, patient-defined goals, and environmental context to investigate whether a behavior precedes improvement. Such observational data remain vulnerable to unmeasured confounding and reverse causation. Repeated sampling improves temporal resolution, not automatic causal certainty Powell et al. (2017) Kratz et al. (2017).

Cognitive Behavioral Interventions and Mechanisms of Change

Cognitive behavioral therapy for MS-related fatigue typically integrates collaborative formulation with changes in sleep routines, activity organization, symptom interpretation, problem-solving, and behavior patterns. Its content should be specified rather than treated as an undifferentiated label: protocols vary in dose, delivery, emphasis, therapist contact, and target population. The most relevant causal question is whether a structured intervention changes fatigue-related functioning more than an appropriate comparator, and whether the effect persists when support ends. Reviews of CBT trials have reported beneficial average effects, although evidence quality, treatment comparisons, and follow-up periods vary van den Akker et al. (2016) Vo et al. (2024).

TREFAMS-ACE supplied a particularly instructive test. Van den Akker and colleagues randomized 91 patients to individual CBT or consultations with an MS nurse and followed outcomes through 52 weeks. The between-group difference favored CBT for fatigue at week 16, with an estimated difference of −6.7 points on the Checklist Individual Strength fatigue subscale (95% CI −10.7 to −2.7). By week 52 the estimated difference was 0.5 points (95% CI −3.6 to 4.4). The authors found no clinically relevant societal-participation effect. These results establish an important distinction between a short-term reduction in fatigue ratings and durable change in life participation van den Akker et al. (2017).

Other CBT-based programs have pursued maintenance through group formats and booster sessions. A later multicenter trial of a FACETS+ program with booster sessions reported a statistically significant twelve-month advantage over standard care for fatigue impact, addressing a problem identified by short-term treatment studies. Differences in populations, treatment intensity, comparator conditions, and scales limit direct claims that one CBT variant is the universally optimal method. A sound synthesis evaluates which outcomes the protocol was designed to change and how fidelity and adherence were measured Gay et al. (2024) Thomas et al. (2013).

CBT mechanisms cannot be inferred solely from symptom change. Demonstrating mediation requires repeated measures of the proposed process, valid instruments, appropriate temporal ordering, and ideally randomized manipulation of specific therapeutic components. An intervention may work by increasing self-efficacy, improving sleep opportunity, reducing task overload, changing catastrophic expectations, or enabling more efficient planning. These explanations need direct comparative investigation. Psychological treatment is appropriately studied as one means of altering the functional burden of MS, within a condition whose biological pathology remains independently established van den Akker et al. (2017) Vo et al. (2024).

Energy Conservation, Activity Pacing, and Occupational Therapy

Energy-conservation education teaches people to assess priorities, modify tasks, distribute physical or cognitive demands, use assistive resources, delegate selected activities, and organize opportunities for recovery. In MS rehabilitation, the value of such strategies depends on whether they protect meaningful participation rather than merely lowering the amount of activity. A plan that conserves energy for paid work, childcare, or social connection can have different value from a plan that minimizes exertion in the abstract. Occupational therapy investigates this relationship between capacities, routines, and environmental demands Mathiowetz et al. (2005) WHO (2001).

The randomized energy-conservation course tested by Mathiowetz and colleagues found improvements in selected fatigue-impact and quality-of-life domains and increased reported self-efficacy. A subsequent survey among course participants suggested adoption of rest, delegation, and changed standards or priorities, but retrospective reports of strategy usefulness cannot isolate cause from preference or prior habit. The one-year follow-up is informative for maintenance, although the trial's delayed-intervention design complicates clean between-group comparisons after treatment crossover Mathiowetz et al. (2005) Mathiowetz et al. (2007) Matuska et al. (2007).

Pacing involves organizing activity and rest in light of anticipated capacity and observed symptom patterns. Its scientific examination needs to separate flexible regulation from prolonged activity restriction and specify whether the outcome is symptom intensity, task completion, physical conditioning, or valued social involvement. Rigid avoidance can sometimes reduce short-term fatigue exposure while narrowing long-term opportunity; conversely, unadapted activity targets can impose excessive burdens. Individualized pacing can therefore be evaluated most clearly with time-use data, personalized participation goals, and repeated measures rather than a simple instruction to rest more Enoka et al. (2021) Powell et al. (2017).

The FACETS group program integrates cognitive-behavioral and energy-management elements, illustrating how these approaches can interact in a real rehabilitation protocol. It also poses a mechanistic challenge: improvement after a multicomponent intervention does not identify which component produced the benefit. Factorial designs, dismantling studies, and process-sensitive data are required to distinguish the effects of scheduling, coping, peer contact, therapist attention, and behavioral experimentation. Group delivery additionally brings potential benefits and barriers involving accessibility, transport, fatigue during sessions, and the exchange of lived experience Thomas et al. (2013) Gay et al. (2024).

Exercise, Physical Conditioning, and Rehabilitation Capacity

Exercise research addresses several overlapping outcomes: cardiorespiratory fitness, muscle strength, balance, walking capacity, fatigue intensity, and participation. Training is potentially relevant because poor conditioning can raise the relative effort of ordinary activity, while structured exercise may alter confidence, mobility, and sleep. However, the ability to complete a laboratory exercise protocol does not by itself establish that participation has increased. Mobility phenotype, heat sensitivity, disability level, recovery time, and safety needs must inform the study design Heine et al. (2015) NICE (2022/2026).

The 2015 Cochrane review by Heine and colleagues synthesized trials of exercise for fatigue. Among 26 trials with non-exercise controls, pooled fatigue outcomes favored exercise (standardized mean difference −0.53, 95% CI −0.73 to −0.33), with substantial heterogeneity. The reviewers emphasized that several trials did not recruit on fatigue criteria, did not target fatigue specifically, or did not use a validated fatigue outcome as the primary endpoint. This limits the precision of an individualized treatment prediction despite a favorable average direction Heine et al. (2015).

Recent syntheses broaden the evidence base but require careful interpretation. A 2026 umbrella review of structured exercise reported the most consistent review-level evidence for cardiorespiratory exercise (Hedges' g approximately −0.376), while resistance exercise showed a moderate pooled association with greater heterogeneity. Overlap among systematic reviews means that their pooled study counts cannot simply be added together as independent trials. Incomplete reporting of frequency, intensity, time, type, volume, and progression also impedes identification of optimal exercise parameters for particular MS populations Rubio-Arias et al. (2026).

NICE recommends discussing aerobic, resistance, balance, yoga, and Pilates-type activities as possible aids for fatigue and specifically considers supervised combined exercise and cognitive-behavioral techniques for people with more impaired mobility. These are clinical guideline positions, not guarantees of benefit in every individual. Distinguishing symptom relief from fitness gains and from social participation remains essential; research should document both adverse events and the practical feasibility of attendance, recovery, transportation, and adaptation NICE (2022/2026) Heine et al. (2015).

Pharmacological Interventions and Comparative Effectiveness

Pharmacological studies provide a necessary counterpoint to behavioral treatment research because fatigue can be disabling even when sleep, mood, and activity have been evaluated. Amantadine, modafinil, and stimulant medications have been used clinically in different settings; evidence for their specific effects on MS fatigue is heterogeneous, and treatment carries adverse-event risks and regulatory differences. No medication discussion in this monograph constitutes an individual prescription, and comparative study results must remain tied to the doses, samples, and follow-up periods actually tested Nourbakhsh et al. (2021) NICE (2022/2026).

TRIUMPHANT-MS was a randomized, double-blind, placebo-controlled, four-period crossover trial. Among 141 randomized patients, 136 contributed to the intention-to-treat analysis. Mean estimated MFIS values at maximal tolerated dose were 40.6 for placebo, 41.3 for amantadine, 39.0 for modafinil, and 38.6 for methylphenidate, with no statistically significant overall medication effect (p = .20). Adverse events were more frequent with each active medication than with placebo. The inference concerns the specific short-term comparisons investigated, including the possibility of carryover and the limits of the studied doses Nourbakhsh et al. (2021).

COMBO-MS used a different design: 336 adults were randomized to telephone-delivered CBT, modafinil, or their combination for twelve weeks. The three groups reported mean within-group MFIS improvements of 15.2, 16.9, and 17.3 points, respectively; adjusted comparisons showed no meaningful between-group advantage for the combination. Because all arms received active treatment, the design could compare therapeutic strategies but did not independently determine how each would perform against placebo or usual care. Sleep quality and sleepiness were prespecified or examined as potentially informative sources of treatment-response heterogeneity Braley et al. (2024).

The coexistence of these trials discourages simplistic conclusions. A drug can fail to outperform placebo in one design while an active-treatment group improves in another, because treatment context, eligibility, expected benefit, baseline variation, comparator, and measurement differ. NICE recommends a specialist-led shared decision process when a person wishes to consider medication for fatigue and flags potential benefits, risks, and safety concerns, including regulatory cautions about modafinil in pregnancy and contraception. These recommendations are jurisdiction-specific and do not establish approved U.S. indications for any particular off-label use NICE (2022/2026) Nourbakhsh et al. (2021).

Self-Management as a Psychological and Social Process

Self-management in MS extends beyond compliance with a treatment regimen. It involves recognizing patterns of symptoms, distinguishing events that require clinical contact, using information to make choices, negotiating assistance, managing treatment burden, and sustaining roles that give everyday life structure. The self-management construct includes observable behavior, knowledge, agency, confidence, and communication. An increase in a self-management scale score is meaningful, but the relationship between that change and fatigue, health outcomes, or participation must be demonstrated empirically Koçak & Arslan (2026) WHO (2001).

A 2026 randomized trial by Koçak and Arslan evaluated an eight-week nurse-led interactive program with 38 participants in each of the intervention and control groups. The intervention improved self-management scores relative to control, but significant changes in fatigue or anxiety were not observed. This result is especially valuable because it prevents self-management from being treated as a proxy for every health outcome. Behavioral capacity to organize care can improve before or without detectable symptom relief, and the limited sample restricts confidence about subgroup effects or longer-term outcomes Koçak & Arslan (2026).

Self-management interventions may target sleep hygiene, stress management, exercise behavior, treatment communication, and cognitive strategies. A 2023 randomized waitlist-controlled study evaluated a seven-week web-based wellness program without individualized counseling, reflecting interest in scalable patient-directed formats. Studies of this kind must distinguish engagement, completion, behavioral adoption, and actual health outcomes; absence of tailored assistance can reduce cost while also changing adherence and accessibility. Waitlist controls cannot separate every specific therapeutic ingredient from attention and expectancy Titcomb et al. (2023).

A person with MS also self-manages within a clinical and family system. Access to occupational therapy, specialist consultation, understandable information, financial support, workplace accommodations, and reliable follow-up influences the ability to carry out a plan. Assignment of all responsibility to the individual confuses self-management with self-sufficiency. Collaborative goal-setting and shared decisions allow people to select which outcomes matter and to weigh trade-offs among symptom burden, treatment risks, effort, and participation NICE (2022/2026) WHO (2001).

Digital Delivery, Reach, and Intervention Fidelity

Digital fatigue interventions can reduce travel demands, support asynchronous participation, and facilitate symptom monitoring. They can also exclude people with visual difficulties, cognitive impairment, limited digital literacy, poor connectivity, or restricted privacy. A digital program is an intervention-delivery medium and not evidence of a common treatment mechanism; online psychoeducation, therapist-guided CBT, autonomous modules, and nurse-led coaching are materially different approaches Koçak & Arslan (2026) Protopapa et al. (2026).

A multicenter randomized noninferiority study compared blended CBT, combining online modules with therapist guidance, against face-to-face CBT among 166 people with severe MS fatigue. The results supported noninferiority on the study's primary post-treatment fatigue outcome within its prespecified margin, providing evidence that some supervised hybrid formats can preserve measured benefit. Noninferiority to an active comparator does not establish superiority to no treatment, and fidelity, attrition, and patient selection still condition the result de Gier et al. (2023).

Protopapa and colleagues reported a 2026 randomized comparison of twelve-week self-guided CBT-based digital treatment versus psychoeducation. Among 129 enrolled participants with fatigue, within-group improvements were observed, but the between-group difference did not demonstrate superiority for the CBT-based program over psychoeducation (mean difference 1.8 points; 95% CI −2.0 to 5.6; p = .35). This contrast is methodologically important: favorable within-arm trajectories can coexist with an uncertain intervention-specific effect Protopapa et al. (2026).

A future digital evidence program should measure exposure to the therapeutic components, accessibility, adverse experiences, sustained engagement, and participation outcomes. Automated reminders may improve adherence but can also become burdensome. Adaptive scheduling based on fatigue reports is a promising testable design, yet monitoring must not be assumed to deliver clinical benefit without randomized evaluation. Patient data protection, the right to disengage, and clinician responsibility are part of responsible implementation Koçak & Arslan (2026) Protopapa et al. (2026).

Participation and the ICF Model of Disability

Participation is involvement in life situations, and its scientific analysis asks whether people can carry out activities they value within the environments in which they actually live. The ICF places participation in a relational system of bodily functioning, activities, personal factors, and environmental circumstances. In MS, fatigue can reduce available time or make engagements uncertain, but participation is also influenced by accessible transport, flexible working conditions, family labor, technological aids, financial resources, and attitudes toward disability. These factors should enter the causal account as measured determinants, not as anecdotal background WHO (2001).

The distinction between capacity and performance is especially productive. Capacity refers to what someone can accomplish under specified conditions; performance concerns activity in their ordinary environment. A participant may demonstrate adequate cognitive accuracy in a quiet assessment room but be unable to sustain a demanding shift with interruptions, heat, and little rest. Conversely, assistive technology and flexible schedules may permit stable occupational performance despite neurological impairment. The relationship between symptom burden and participation is mediated and moderated by activity organization and environmental design WHO (2001) van Egmond et al. (2024).

Participation has multiple domains, and an aggregated score may conceal ethically and clinically important divergence. One person seeks to remain employed, another values caregiving, another wishes to study, and another prioritizes social involvement. The desired outcome must be elicited rather than inferred from an investigator's preferred benchmark. Self-reported participation autonomy and satisfaction can complement indicators such as time at work, missed activities, sustained relationships, and transport access, while each measures a different facet van den Akker et al. (2017) Hobart et al. (2001).

The TREFAMS-ACE findings illustrate why participation deserves its own endpoint. Despite an intervention-related improvement in short-term fatigue, the trial did not establish a clinically relevant change in societal participation. Possible explanations include insufficient follow-up, weak treatment effects on contextual obstacles, inadequate responsiveness of the participation measure, or genuinely separate causal pathways. The trial alone does not decide among these explanations. It does establish that fatigue and participation should be analyzed independently van den Akker et al. (2017).

Employment, Cognitive Complaints, and Social Roles

Employment can be affected by fatigue intensity, cognitive complaints, physical limitation, employment flexibility, and discrimination. It also varies with the economic context, occupational demands, social insurance, and the timing of diagnosis. A useful longitudinal study asks who remains employed, changes hours or responsibilities, leaves employment, or reenters the workforce and then examines the predictors of these transitions. A cross-sectional comparison of employed and unemployed patients cannot separate selection from consequences or measure trajectories adequately van Egmond et al. (2024).

Van Egmond and colleagues followed 170 employed people with relapsing-remitting MS with annual assessments over three years. Higher baseline fatigue impact, depressive symptoms, cognitive complaints, and lower workplace support were associated with deteriorated employment status. These associations were reported in a longitudinal design, giving more temporal information than a single survey, but they still do not demonstrate that intervening on any one factor would independently prevent employment loss. The workplace support finding indicates that participation outcomes depend in part on modifiable social conditions van Egmond et al. (2024).

Cognitive fatigue must be examined alongside cognitive impairment. Perceived concentration difficulty may fluctuate with load and sleep, while objective neuropsychological measures assess performance under specific test conditions. People may use compensatory techniques such as task grouping, reminders, scheduled breaks, or reduced interruptions. Whether these strategies preserve performance over a workday requires measurement outside the clinic. Including both self-report and observer or employment outcomes reduces the risk of mistaking one measurement domain for the whole phenomenon Kratz et al. (2017) van Egmond et al. (2024).

The meaning of work also varies. Employment may supply identity, financial security, social contact, and future opportunity; it may also impose burdens that threaten health or exclude meaningful family participation. Individual rehabilitation decisions should therefore be evaluated against patient-defined priorities and informed choice. Research that measures only paid hours can miss the value of unpaid caregiving or education and may implicitly penalize people whose circumstances require a different allocation of limited energy WHO (2001) van den Akker et al. (2017).

Life Course, Relationships, and the Burden of Coordination

MS commonly begins during periods when people are establishing employment, family relationships, education, or long-term roles, but it can affect people across a wide age range. Diagnostic practice has evolved, and the 2024 McDonald criteria, published in 2025, accommodate relapsing and progressive presentations across the life span. These are diagnostic developments; the psychological research task is to study how people reorganize activities and expectations under trajectories that may change over years Montalban et al. (2025).

Longitudinal analysis matters because the functional consequences of fatigue may accumulate gradually. A manageable weekly burden may become more disruptive when job requirements intensify, caregiving responsibilities increase, or transport becomes unreliable. Conversely, workplace adjustment and social support may allow continued participation without a change in neurological disease. Researchers should avoid treating a single disability score as a complete biography and should examine transitions, attrition, and changing priorities through repeated interviews and quantitative follow-up WHO (2001) van Egmond et al. (2024).

Close relationships are both contexts of fatigue and resources for coping. Family members may help with transportation, medication logistics, household labor, and emotional coordination. Such support can preserve valued participation, yet unequal division of labor, concerns about dependency, and unspoken expectations may produce conflict. The proper psychological outcome is not maximum independence in every task; it is agency within sustainable arrangements that are acceptable to the people involved. Research should evaluate patient and partner perspectives where possible rather than assigning one informant universal authority WHO (2001).

Treatment burden also has a time dimension. Appointments, monitoring, travel, paperwork, and administrative requirements may compete directly with rest, work, and social time. An intervention with a favorable fatigue score but a demanding delivery schedule can still impose an unacceptable net burden. Pragmatic research needs to record service use, travel, access barriers, caregiver time, and the costs of participation in treatment. Digital and hybrid care can reduce selected barriers while introducing others Braley et al. (2024) de Gier et al. (2023).

Heterogeneity, Equity, and External Validity

The MS population is heterogeneous with respect to course, disability, comorbidities, age, socioeconomic resources, cognition, and opportunity to participate. Studies frequently recruit ambulatory participants from specialist centers, use minimum fatigue thresholds, and exclude unstable medical conditions. These criteria can improve internal validity but narrow the populations to which outcomes may be transported. A trial involving predominantly younger and ambulatory adults does not automatically provide a reliable prediction for older people with severe mobility impairment Kratz et al. (2017) Braley et al. (2024).

COMBO-MS enrolled 336 adults across three active-treatment arms; 76.2% of the participants were women, 85.1% were White, and 71.1% had relapsing MS in the associated detailed trial report. Those characteristics help interpret the evidence. Geographic and demographic representation, treatment access, and eligibility should be examined before generalizing the observed reductions to all forms of MS or all healthcare settings. Subgroup comparisons need sufficient power and prespecified interaction tests to avoid generating unstable claims Braley et al. (2024).

Context also influences the feasibility of self-management. People with limited household income may have less control over work schedules, access to cooling, transportation, treatment time, digital tools, or private space for therapy. The instruction to prioritize, rest, or exercise assumes resources that are unevenly distributed. A fair intervention evaluation should measure whether the treatment is reachable and whether the participant has material means to implement it. Equity is relevant to external validity because an intervention that works only under unusually favorable conditions has limited real-world effectiveness WHO (2001) NICE (2022/2026).

International comparisons need attention to health-system organization and measurement equivalence. The NICE guideline provides a well-documented UK context, but its service pathways, cost-effectiveness decisions, and off-label medication options should not be translated mechanically into U.S. prescribing claims. Likewise, fatigue instruments validated in one language or disability range require investigation before pooling outcomes across countries. Cross-cultural validity is part of scientific measurement, not only a translation issue Kos et al. (2005) NICE (2022/2026).

Research Designs, Causal Inference, and Bias

Randomized controlled trials can estimate the effects of assigned interventions when allocation is concealed, follow-up is sufficiently complete, and outcomes are prespecified. In fatigue research, treatment blinding can be difficult for behavioral therapies and exercise. Therapist attention, expectation, and differences in comparison conditions can affect self-reported outcomes. For many psychological interventions, the strongest design includes an active comparator, assessor masking where possible, intention-to-treat analysis, transparent attrition reporting, and sensitivity analysis for missing data van den Akker et al. (2017) Braley et al. (2024).

Crossover studies can efficiently compare several medicines when participants serve as their own controls, but carryover, period effects, and fluctuating symptoms complicate analysis. TRIUMPHANT-MS used washout periods and masking, yet its authors recognized that residual carryover and changes in fatigue over time might influence estimates. A null average result can coexist with individual response variation, but post hoc identification of responders should not be mistaken for a validated treatment-selection rule Nourbakhsh et al. (2021).

Longitudinal cohorts reveal trajectories and predictors without assigning interventions. They are well suited to questions about employment deterioration, fatigue fluctuations, and self-management adoption. Still, apparent predictive relationships can reflect unmeasured disease severity, preexisting socioeconomic conditions, differential dropout, or other confounding. EMA improves resolution of temporal ordering, but within-person associations do not themselves demonstrate causal mediation. Randomized manipulation of a candidate mechanism is needed to strengthen such claims Powell et al. (2017) Kratz et al. (2017) van Egmond et al. (2024).

Evidence synthesis presents further hazards. Systematic reviews differ in inclusion criteria, fatigue definitions, scales, and analytic methods. Umbrella reviews may count the same primary study repeatedly across overlapping meta-analyses. Large pooled standardized effects from heterogeneous small trials can have less credibility than a modest effect reproduced across independent well-conducted studies. The 2026 umbrella reviews explicitly noted heterogeneity, review overlap, and generally limited methodological confidence in some evidence streams. Ranking interventions by point estimates alone ignores these limitations Hawas et al. (2026) Rubio-Arias et al. (2026).

Safety, Clinical Boundaries, and Patient-Centered Evaluation

Assessment of fatigue in a person with diagnosed MS should consider medical explanations and comorbid conditions rather than assuming a purely psychological pathway. The NICE recommendations call for recognition of sudden or changing fatigue, clinical evaluation of potentially contributing sleep, medical, treatment-related, and emotional factors, and personalized discussion of self-management. The guideline also recommends specialist-led discussion for medication options and warns against particular unsupported interventions. These positions provide a responsible clinical frame for scientific interpretation NICE (2022/2026).

The evidence does not support presenting MS fatigue as a sign of weak motivation, insufficient effort, or poor self-discipline. Such descriptions substitute moral judgment for measurement and can increase the burden of social participation. Psychological interventions are most defensible when they enhance available choices, clarify goals, reduce avoidable symptom amplifiers, and work alongside appropriate neurological, rehabilitation, and social support. Patient agency includes the ability to reject a burdensome intervention after an informed discussion WHO (2001) NICE (2022/2026).

Risk monitoring is relevant even for nonpharmacological treatment. Exercise studies should record falls, heat-related worsening, recovery demands, and adverse experiences; psychological programs should monitor deterioration, unacceptable burden, and barriers to attendance. For pharmacological interventions, trial-level efficacy must be considered alongside adverse events, interactions, pregnancy risks, and local regulatory status. TRIUMPHANT-MS observed more adverse events with each tested active medication than with placebo, emphasizing the importance of benefit-risk evaluation Nourbakhsh et al. (2021) Heine et al. (2015).

A scientifically strong outcome set includes symptom ratings, task-relevant performance, patient-valued participation, treatment burden, and adverse effects. The evaluation should specify who selected the goal, how meaningful change was defined, and whether the person could sustain the benefit beyond the active intervention. Involving patients in study design helps identify outcomes that professional investigators may otherwise overlook. The final criterion of rehabilitation success is the improvement of functioning and opportunity that the affected person values, interpreted alongside measurable health and safety WHO (2001) van den Akker et al. (2017).

Critical Comparison of Intervention Evidence

The accumulated evidence supports a differentiated account of fatigue interventions. CBT trials provide evidence that structured psychological and behavioral treatment can reduce patient-reported fatigue relative to some active comparators, particularly near the end of treatment. Occupational energy-conservation programs can improve fatigue impact and practical strategy use. Exercise programs provide a favorable average effect on self-reported fatigue in evidence syntheses, with variation across modality and study quality. Pharmacological trials have produced less consistent results; a rigorously controlled comparison of amantadine, modafinil, methylphenidate, and placebo found no overall advantage of the tested drugs. These findings should be interpreted jointly, with attention to primary outcomes, comparators, adherence, follow-up, and adverse events van den Akker et al. (2017) Mathiowetz et al. (2005) Heine et al. (2015) Nourbakhsh et al. (2021).

A central distinction concerns the comparator. The placebo-controlled TRIUMPHANT-MS trial was capable of evaluating drug benefit beyond placebo under its particular four-period crossover protocol. COMBO-MS compared three active strategies, finding substantial within-arm improvements with telephone CBT, modafinil, and combined treatment but no superiority of combined treatment. The absence of a placebo or untreated arm in COMBO-MS means its numerical changes cannot be read as the absolute specific therapeutic effect of any individual arm. Both studies contribute to the scientific record without being contradictory: they estimate different comparisons, with different design structures and participant expectations Nourbakhsh et al. (2021) Braley et al. (2024).

A second distinction concerns duration. In TREFAMS-ACE, the short-term CBT advantage on the fatigue subscale was absent at week 52, and a clinically important societal-participation difference was not established. Other trials have tested group CBT and booster formats to strengthen maintenance, while pragmatic digital studies have examined programs designed for ongoing access. The scientific question is whether observed improvement after treatment can be sustained without increasing the burden of participation in care. To answer it, researchers need repeated follow-up, intervention-contact measures, and transparent accounting of treatment adherence and dropout van den Akker et al. (2017) Gay et al. (2024) Protopapa et al. (2026).

A third distinction concerns the level of intervention. The 2026 nurse-led self-management trial improved measured self-management while leaving group-level fatigue and anxiety outcomes statistically unchanged. The 2026 online self-guided CBT study found improvement in participants exposed to treatment, but comparison with psychoeducation did not establish superiority. These results suggest that increased practical competence and declining fatigue are related but independent possible outcomes. Theories of rehabilitation should recognize improvements in decision-making, knowledge, or care coordination as meaningful achievements while requiring separate evidence before asserting symptom reduction Koçak & Arslan (2026) Protopapa et al. (2026).

A fourth distinction concerns quality of evidence. Umbrella syntheses published in 2026 reported favorable directions for several nonpharmacological strategies, especially aerobic or cardiorespiratory exercise, while recognizing heterogeneous populations, varied outcome measures, overlapping reviews, and methodological limitations. Their conclusions are informative at the level of broad intervention classes. They do not establish individualized exercise dose, superiority over a particular behavioral protocol, or reliable predictions of participation gain. Clinical recommendations need to incorporate the stronger direct trials and the limits of review-level estimates together Hawas et al. (2026) Rubio-Arias et al. (2026).

Unresolved Problems and Research Priorities

The first unresolved problem is causal specificity. Biological pathology, subjective effort, mood, expectations, sleep, environmental resources, and treatment effects may influence one another over time. Many observational reports use cross-sectional data or retrospectively summarized symptoms; such designs establish associations but leave direction and mediation uncertain. Research that directly changes task demands, recovery opportunities, or intervention components while measuring repeated outcomes would distinguish some plausible mechanisms and improve causal explanation Powell et al. (2017) Kluger et al. (2013).

The second problem is durability. Some behavioral effects are measured directly after a structured course, when therapist support and participant attention are greatest. Their persistence after six months or several years is less securely known. Trials need prespecified long-term outcomes, complete reporting of subsequent care, and methods for informative dropout. Participation changes may require a longer causal horizon than fatigue ratings, particularly when employment arrangements and family roles change slowly van den Akker et al. (2017) Mathiowetz et al. (2007).

The third problem is construct validity. Researchers need to distinguish perceived fatigue, fatigue impact, effort, objective cognitive or motor fatigability, self-management, activity levels, and participation. Different instruments can produce superficially discordant answers because they measure different targets. Scale-selection rationale, measurement invariance, minimal important change, and triangulation with direct participation measures should be routine elements of major trials Krupp et al. (1989) Kos et al. (2005) Hobart et al. (2001).

The fourth problem is equitable reach. Digital treatment, structured exercise, and occupational therapy require varying levels of time, money, mobility, cognitive capacity, and care access. People with progressive disease, greater disability, rural residence, lower income, or limited technological resources may be poorly represented in some trial samples. Pragmatic recruitment, accessible trial protocols, multilingual measurement, reporting of nonparticipation, and attention to disability accommodations are necessary to estimate effectiveness in broader populations WHO (2001) de Gier et al. (2023) Braley et al. (2024).

The fifth problem is treatment selection. The existence of different plausible interventions does not establish which patient should receive which one first. Comparative-effectiveness trials can evaluate strategies in populations with differing sleep disturbances, disability levels, activity preferences, cognitive complaints, and work circumstances. Individual participant data analyses and prospective validation could test whether measured moderators offer useful decision rules. The COMBO-MS comparison provides a model for active-strategy evaluation but also illustrates that broadly similar average outcomes do not automatically identify a personalized algorithm Braley et al. (2024).

The sixth problem is the definition of rehabilitation success. Fatigue reduction is important but participation, autonomy, clinical safety, access, relationship quality, and treatment burden also matter. Future trials should specify at least one validated fatigue outcome, one patient-valued participation outcome, and process measures matched to the proposed mechanism. They should record adverse events, adherence, resource requirements, and long-term effects. Transparent registration and accessible reporting would permit stronger synthesis across methods and jurisdictions WHO (2001) NICE (2022/2026) Hawas et al. (2026).

Conclusion

Multiple sclerosis-related fatigue is a multidimensional, temporally variable experience that can constrain cognitive and physical activity, work, relationships, and participation. Its measurement must distinguish subjective fatigue, fatigue impact, and objective performance fatigability, while careful clinical assessment considers sleep, mood, pain, medication effects, and other potentially modifiable contributors. The historical research program progressed from establishing fatigue as a separate and measurable burden to testing energy conservation, CBT, exercise, pharmacological treatments, and digitally delivered self-management Krupp et al. (1988) Kluger et al. (2013) NICE (2022/2026).

Comparative evidence supports cautious, intervention-specific conclusions. Structured behavioral and rehabilitation approaches can improve selected fatigue or functioning outcomes. Exercise reviews generally favor appropriately designed training, with substantial heterogeneity. TRIUMPHANT-MS found no overall benefit of three tested medications over placebo; COMBO-MS found no advantage of combining CBT and modafinil over the two individual active strategies. Self-management improvements and fatigue reductions can diverge, and improvement in fatigue scores does not automatically produce improved participation Heine et al. (2015) Nourbakhsh et al. (2021) Braley et al. (2024) Koçak & Arslan (2026).

The central scientific synthesis is that fatigue, self-management, and participation are three interdependent but independently measurable dimensions of MS-related functioning. Neurological disease affects what people can do, psychological and behavioral organization affects how activity is negotiated, and social and material environments affect whether valued opportunities are available. A complete rehabilitation evidence base must establish changes in symptoms, capacities, agency, and lived participation, test whether those changes last, and examine for whom and under which circumstances interventions work. That framework provides a coherent basis for research, responsible clinical interpretation, and more informative future trials WHO (2001) van den Akker et al. (2017) van Egmond et al. (2024).

References

  • Braley, T. J., Ehde, D. M., Alschuler, K. N., Little, R., Ng, Y. T., Zhai, Y., von Geldern, G., Chervin, R. D., Conroy, D., Valentine, T. R., Romeo, A. R., LaRocca, N., Hamade, M., Jordan, A., Singh, M., Segal, B. M., & Kratz, A. L. (2024). Comparative effectiveness of cognitive behavioural therapy, modafinil, and their combination for treating fatigue in multiple sclerosis (COMBO-MS): A randomised, statistician-blinded, parallel-arm trial. The Lancet Neurology, 23(11), 1108–1118. https://doi.org/10.1016/S1474-4422(24)00354-5
  • de Gier, M., Beckerman, H., Twisk, J., Knoop, H., & de Groot, V. (2023). Blended versus face-to-face cognitive behavioural therapy for severe fatigue in patients with multiple sclerosis: A non-inferiority RCT. Multiple Sclerosis Journal, 29(10), 1316–1326. https://doi.org/10.1177/13524585231185462
  • Enoka, R. M., Almuklass, A. M., Alenazy, M., Alvarez, E., & Duchateau, J. (2021). Distinguishing between fatigue and fatigability in multiple sclerosis. Neurorehabilitation and Neural Repair, 35(11), 960–973. https://doi.org/10.1177/15459683211046257
  • Gay, M. C., Cassedanne, F., Barbot, F., Vaugier, I., Thomas, S., Manchon, E., Bensmail, D., Blanchere, M., & Heinzlef, O. (2024). Long-term effectiveness of a cognitive behavioural therapy (CBT) in the management of fatigue in patients with relapsing remitting multiple sclerosis (RRMS): A multicentre, randomised, open-label, controlled trial versus standard care. Journal of Neurology, Neurosurgery & Psychiatry, 95(2), 158–166. https://doi.org/10.1136/jnnp-2023-331537
  • Hawas, Y., Abdelmageed, A., Abouzid, M., Hamad, A. A., El-Moslemani, M., Saeed, H. T., Salama, E. Y., Al Azzawi, M. A. D., Ewis, D. K., Arafa, A., Alnajjar, A. Z., Abo Elnaga, A. A., Khalil, M. M., & Rodrigues, A. C. L. F. (2026). Measurements and management of multiple sclerosis-related fatigue: An umbrella review and meta-analysis. Disability and Rehabilitation, advance online publication. https://doi.org/10.1080/09638288.2026.2711882
  • Heine, M., van de Port, I., Rietberg, M. B., van Wegen, E. E. H., & Kwakkel, G. (2015). Exercise therapy for fatigue in multiple sclerosis. Cochrane Database of Systematic Reviews, 2015(9), CD009956. https://doi.org/10.1002/14651858.CD009956.pub2
  • Hobart, J., Lamping, D., Fitzpatrick, R., Riazi, A., & Thompson, A. (2001). The Multiple Sclerosis Impact Scale (MSIS-29): A new patient-based outcome measure. Brain, 124(5), 962–973. https://doi.org/10.1093/brain/124.5.962
  • Kluger, B. M., Krupp, L. B., & Enoka, R. M. (2013). Fatigue and fatigability in neurologic illnesses: Proposal for a unified taxonomy. Neurology, 80(4), 409–416. https://doi.org/10.1212/WNL.0b013e31827f07be
  • Koçak, A. T., & Arslan, S. (2026). Evaluating nurse-led self-regulation in multiple sclerosis management with an interactive web-based program: A randomized controlled trial. Health Education Research, 41(3), Article cyag011. https://doi.org/10.1093/her/cyag011
  • Kos, D., Kerckhofs, E., Carrea, I., Verza, R., Ramos, M., & Jansa, J. (2005). Evaluation of the Modified Fatigue Impact Scale in four different European countries. Multiple Sclerosis, 11(1), 76–80. https://doi.org/10.1191/1352458505ms1117oa
  • Kratz, A. L., Murphy, S. L., & Braley, T. J. (2017). Ecological momentary assessment of pain, fatigue, depressive, and cognitive symptoms reveals significant daily variability in multiple sclerosis. Archives of Physical Medicine and Rehabilitation, 98(11), 2142–2150. https://doi.org/10.1016/j.apmr.2017.07.002
  • Krupp, L. B., Alvarez, L. A., LaRocca, N. G., & Scheinberg, L. C. (1988). Fatigue in multiple sclerosis. Archives of Neurology, 45(4), 435–437. https://doi.org/10.1001/archneur.1988.00520280085020
  • Krupp, L. B., LaRocca, N. G., Muir-Nash, J., & Steinberg, A. D. (1989). The fatigue severity scale: Application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology, 46(10), 1121–1123. https://doi.org/10.1001/archneur.1989.00520460115022
  • Mathiowetz, V. G., Finlayson, M., Matuska, K. M., Chen, H. Y., & Luo, P. (2005). Randomized controlled trial of an energy conservation course for persons with multiple sclerosis. Multiple Sclerosis, 11(5), 592–601. https://doi.org/10.1191/1352458505ms1198oa
  • Mathiowetz, V. G., Matuska, K. M., Finlayson, M., Luo, P., & Chen, H. Y. (2007). One-year follow-up to a randomized controlled trial of an energy conservation course for persons with multiple sclerosis. International Journal of Rehabilitation Research, 30(4), 305–313. https://doi.org/10.1097/MRR.0b013e3282f14434
  • Matuska, K. M., Mathiowetz, V. G., & Finlayson, M. (2007). Use and perceived effectiveness of energy conservation strategies for managing multiple sclerosis fatigue. American Journal of Occupational Therapy, 61(1), 62–69. https://doi.org/10.5014/ajot.61.1.62
  • Montalban, X., Lebrun-Frénay, C., Oh, J., Arrambide, G., Moccia, M., Amato, M. P., Amezcua, L., Banwell, B., Bar-Or, A., Barkhof, F., Butzkueven, H., Ciccarelli, O., Chataway, J., Cohen, J. A., Comi, G., Correale, J., Deisenhammer, F., Filippi, M., Fiol, J., … Thompson, A. J. (2025). Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. The Lancet Neurology, 24(10), 850–865. https://doi.org/10.1016/S1474-4422(25)00270-4
  • National Institute for Health and Care Excellence. (2022, updated 2026). Multiple sclerosis in adults: Management (NICE guideline NG220). NICE. https://www.nice.org.uk/guidance/ng220/chapter/Recommendations
  • Nourbakhsh, B., Revirajan, N., Morris, B., Cordano, C., Creasman, J., Manguinao, M., Krysko, K., Rutatangwa, A., Auvray, C., Aljarallah, S., Jin, C., Mowry, E., McCulloch, C., & Waubant, E. (2021). Safety and efficacy of amantadine, modafinil, and methylphenidate for fatigue in multiple sclerosis: A randomised, placebo-controlled, crossover, double-blind trial. The Lancet Neurology, 20(1), 38–48. https://doi.org/10.1016/S1474-4422(20)30354-9
  • Piscitelli, D., Brichetto, G., Geri, T., Battista, S., Testa, M., Monti Bragadin, M., & Pellicciari, L. (2024). Italian adaptation and psychometric validation of the Fatigue Impact Scale (FIS) and its modified versions in adults with multiple sclerosis: A Rasch analysis study. Disability and Rehabilitation, 46(22), 5366–5379. https://doi.org/10.1080/09638288.2024.2302878
  • Powell, D. J. H., Liossi, C., Schlotz, W., & Moss-Morris, R. (2017). Tracking daily fatigue fluctuations in multiple sclerosis: Ecological momentary assessment provides unique insights. Journal of Behavioral Medicine, 40(5), 772–783. https://doi.org/10.1007/s10865-017-9840-4
  • Protopapa, M., Samarin, J., Schraad, M., Lang, L. S., Hahn, M., Zipp, F., & Bittner, S. (2026). Real world observation of fatigue in multiple sclerosis comparing self-guided online cognitive behavioral therapy versus psychoeducation. Multiple Sclerosis Journal—Experimental, Translational and Clinical, 12(3), Article 20552173261468118. https://doi.org/10.1177/20552173261468118
  • Rubio-Arias, J. Á., Villena-Molina, S., Andreu-Carvaca, L., Leon-Ariza, H. H., Ferrer-Contreras, M. C., & Ramos-Campo, D. J. (2026). Structured exercise training for fatigue management in multiple sclerosis: An umbrella review of systematic reviews and meta-analyses. Archives of Physical Medicine and Rehabilitation, advance online publication. https://doi.org/10.1016/j.apmr.2026.07.021
  • Thomas, S., Thomas, P. W., Kersten, P., Jones, R., Green, C., Nock, A., Slingsby, V., Smith, A. D., Baker, R., Galvin, K. T., & Hillier, C. (2013). A pragmatic parallel arm multi-centre randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based fatigue management programme (FACETS) for people with multiple sclerosis. Journal of Neurology, Neurosurgery & Psychiatry, 84(10), 1092–1099. https://doi.org/10.1136/jnnp-2012-303816
  • Titcomb, T. J., Sherwood, M., Ehlinger, M., Saxby, S. M., Shemirani, F., Ten Eyck, P., Wahls, T. L., & Snetselaar, L. G. (2023). Evaluation of a web-based program for the adoption of wellness behaviors to self-manage fatigue and improve quality of life among people with multiple sclerosis: A randomized waitlist-control trial. Multiple Sclerosis and Related Disorders, 77, Article 104858. https://doi.org/10.1016/j.msard.2023.104858
  • van den Akker, L. E., Beckerman, H., Collette, E. H., Eijssen, I. C. J. M., Dekker, J., & de Groot, V. (2016). Effectiveness of cognitive behavioral therapy for the treatment of fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. Journal of Psychosomatic Research, 90, 33–42. https://doi.org/10.1016/j.jpsychores.2016.09.002
  • van den Akker, L. E., Beckerman, H., Collette, E. H., Twisk, J. W. R., Bleijenberg, G., Dekker, J., Knoop, H., & de Groot, V. (2017). Cognitive behavioral therapy positively affects fatigue in patients with multiple sclerosis: Results of a randomized controlled trial. Multiple Sclerosis, 23(11), 1542–1553. https://doi.org/10.1177/1352458517709361
  • van Egmond, E. E. A., van der Hiele, K., de Rooij, M. J., van Gorp, D. A. M., Jongen, P. J., van der Klink, J. J. L., Reneman, M. F., Beenakker, E. A. C., van Eijk, J. J. J., Frequin, S. T. F. M., de Gans, K., Hoitsma, E., Gerlach, O. H. H., Mostert, J. P., Verhagen, W. I. M., Visser, L. H., & Middelkoop, H. A. M. (2024). Longitudinal determinants of employment status in people with relapsing-remitting multiple sclerosis. IBRO Neuroscience Reports, 16, 518–526. https://doi.org/10.1016/j.ibneur.2024.04.002
  • Vo, H. L. T., Elias, S., & Hardy, T. A. (2024). Cognitive behavioural therapy for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis. Multiple Sclerosis and Related Disorders, 91, Article 105908. https://doi.org/10.1016/j.msard.2024.105908
  • World Health Organization. (2001). International classification of functioning, disability and health: ICF. World Health Organization. https://www.who.int/standards/classifications/international-classification-of-functioning-disability-and-health